
"Session Shows a Real Rally Building"
By James J. Cramer
RealMoney Columnist
2/18/2004 4:34 PM EST
"We get 8-point spikes on drug approvals, court wins and earnings surprises. Tuesday's spike was on Reuters (RTRSY:Nasdaq ADR - commentary - research). Today's spikes are on Rambus (RMBS:Nasdaq - commentary - research) and Biogen Idec (BIIB:Nasdaq - commentary - research). I don't know about you, but when looking for takeaways of the last few days, I would seize on the ability to make big money on news that's not about takeovers.
In the late 1990s, we became accustomed to the up 12-down-12-up world as disappointments crushed stocks and surprises buoyed them. In retrospect, though, many of those pump-ups were pure short-squeezes, the legacy of stocks being run up by unscrupulous hedge funds.
Now, stocks run up big not on short-squeezes -- neither Biogen Idec nor Reuters nor Rambus had huge short positions coming into their bountiful sessions, although all were larger at one time -- but on animal enthusiasm. It may not be any healthier in the eyes of some of you, but I like real rallies based on interest, not phony rallies based on squeezes, even as the profits you make if you are long are no different.
One is an edifice that can give back a few bricks but rally again, the other is pure quicksand that will later give it back in gobs, as happened after the 1999 bull.
I know that some of you will focus on the decline of the broader averages today, but I think that's more option expiration than anything else. I expect it to be reversed later in the week. "
(in www.realmoney.com)
By James J. Cramer
RealMoney Columnist
2/18/2004 4:34 PM EST
"We get 8-point spikes on drug approvals, court wins and earnings surprises. Tuesday's spike was on Reuters (RTRSY:Nasdaq ADR - commentary - research). Today's spikes are on Rambus (RMBS:Nasdaq - commentary - research) and Biogen Idec (BIIB:Nasdaq - commentary - research). I don't know about you, but when looking for takeaways of the last few days, I would seize on the ability to make big money on news that's not about takeovers.
In the late 1990s, we became accustomed to the up 12-down-12-up world as disappointments crushed stocks and surprises buoyed them. In retrospect, though, many of those pump-ups were pure short-squeezes, the legacy of stocks being run up by unscrupulous hedge funds.
Now, stocks run up big not on short-squeezes -- neither Biogen Idec nor Reuters nor Rambus had huge short positions coming into their bountiful sessions, although all were larger at one time -- but on animal enthusiasm. It may not be any healthier in the eyes of some of you, but I like real rallies based on interest, not phony rallies based on squeezes, even as the profits you make if you are long are no different.
One is an edifice that can give back a few bricks but rally again, the other is pure quicksand that will later give it back in gobs, as happened after the 1999 bull.
I know that some of you will focus on the decline of the broader averages today, but I think that's more option expiration than anything else. I expect it to be reversed later in the week. "
(in www.realmoney.com)